Novo Nordisk Expected to File Oral Wegovy for Weight Loss in China Within Months
0xBroomberg
Novo Nordisk's CEO says the company will file for Chinese approval of oral Wegovy within months — a pivotal injection-to-pill shift as competition in China's weight-loss drug market intensifies.
When is oral Wegovy coming to China?
New CEO Mike Doustdar, on his first China visit since taking the role in August, said Novo Nordisk will submit a regulatory filing for oral Wegovy within months.
This means → Novo Nordisk is accelerating its push to bring an oral weight-loss drug already approved in the U.S. and U.K. into China, on a tighter timeline than the market expected.
Oral Wegovy launched in the U.S. this year. If China's filing proceeds smoothly, Chinese patients could have access to a weight-loss pill within one to two years.
Why are drugmakers racing to make a pill?
Today's leading weight-loss drugs — Wegovy and Ozempic — are injections. Many patients avoid them simply because they dislike needles.
In plain terms = a pill has a far lower barrier — no clinic visit, no self-injection. Patient uptake is naturally higher.
Both Novo Nordisk and Eli Lilly are betting on oral formats. Lilly's oral drug orforglipron — a GLP-1 drug that mimics gut hormones to suppress appetite and slow stomach emptying — won U.S. approval in April this year.
How fierce is competition in China?
Lilly has already moved first: it submitted a Chinese filing for once-daily oral orforglipron at the end of 2025, ahead of Novo Nordisk.
Bigger pressure comes from generics. The Chinese patent on semaglutide — the active ingredient in Wegovy and Ozempic — expired in March this year. Doustdar expects generic competition to begin from Q2 next year.
Domestic players Innovent Biologics (信达生物) and Pfizer have also entered the market, though none have disclosed China sales figures.
With the patent expired, what moat does Novo Nordisk still have?
Despite the patent expiry, Novo Nordisk retains regulatory data protection — a statutory exclusivity period that prevents generic makers from referencing the originator's clinical data to file for approval. It runs until early next year.
This means → generic firms cannot yet free-ride on Novo's clinical dossier. Even without patent protection, they still need to complete their own trial process.
Doustdar also stressed that the manufacturing scale-up for oral weight-loss drugs is itself a barrier. Put simply = formulating a pill is one thing; mass-producing it reliably is another — a real technical challenge for would-be generic entrants.
How big is China's weight-loss drug market right now?
The honest answer: it is not transparent. Major players including Innovent and Lilly have not disclosed China-specific sales data.
Jefferies data shows total Chinese GLP-1 drug sales through major e-commerce platforms like Alibaba and JD.com reached roughly RMB 1.4 billion (about $207 million) in Q1 this year.
This reflects a market still in its early stages — but with significant growth potential. The arrival of oral drugs could substantially expand the total user base.
Content is for reference only, not financial advice.